Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q8083967> ?p ?o }
Showing triples 1 to 58 of
58
with 100 triples per page.
- Q8083967 subject Q20740287.
- Q8083967 subject Q6870315.
- Q8083967 subject Q7441579.
- Q8083967 subject Q8872471.
- Q8083967 subject Q8965786.
- Q8083967 subject Q9672646.
- Q8083967 abstract "α5IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABAA receptor. It binds to the α1, α2, α3 and α5 subtypes, but shows much higher efficacy at the α5 subtype, and acts either as a weak partial agonist or inverse agonist at the other subtypes, with its partial agonist effect at α2 likely to be responsible for the lack of anxiety produced by this drug when compared to older α5-preferring inverse agonists such as L-655,708.The α5 subtype is expressed predominantly in the hippocampus, an area of the brain involved with learning and memory, and activation of this subtype is thought to be largely responsible for producing the cognitive side effects displayed by many benzodiazepine and nonbenzodiazepine drugs, such as amnesia and difficulties with learning and memory. This led researchers to conclude that a drug acting as an inverse agonist at this subtype should have the opposite effect and enhance learning and memory.Older non-selective inverse agonists at the benzodiazepine site such as DMCM are associated with a range of other effects including anxiety and convulsions, but because α5IA acts specifically at the α5 subtype it produces nootropic effects in animal studies, yet without any significant anxiogenic or pro-convulsant effects. This gives α5IA the potential to be a useful drug either to be used alongside benzodiazepines to counteract their cognitive side effects, or by itself as a nootropic with possible applications in the treatment of Alzheimer's disease and other forms of dementia.".
- Q8083967 atcPrefix "none".
- Q8083967 casNumber "215874-86-5".
- Q8083967 iupacName "3-​(5-​methylisoxazol-​3-​yl)-​6-​[(1-​methyl-​1H-​1,2,3-​triazol-​4-​yl)​methoxy]​[1,2,4]triazolo​[3,4-​a]phthalazine".
- Q8083967 pubchem "6918451".
- Q8083967 thumbnail Alpha5IA.png?width=300.
- Q8083967 wikiPageWikiLink Q11072.
- Q8083967 wikiPageWikiLink Q11081.
- Q8083967 wikiPageWikiLink Q15410190.
- Q8083967 wikiPageWikiLink Q154430.
- Q8083967 wikiPageWikiLink Q1671731.
- Q8083967 wikiPageWikiLink Q18025042.
- Q8083967 wikiPageWikiLink Q18025054.
- Q8083967 wikiPageWikiLink Q18025063.
- Q8083967 wikiPageWikiLink Q18025082.
- Q8083967 wikiPageWikiLink Q20707932.
- Q8083967 wikiPageWikiLink Q20740287.
- Q8083967 wikiPageWikiLink Q208467.
- Q8083967 wikiPageWikiLink Q247489.
- Q8083967 wikiPageWikiLink Q4262284.
- Q8083967 wikiPageWikiLink Q4778117.
- Q8083967 wikiPageWikiLink Q48360.
- Q8083967 wikiPageWikiLink Q5205608.
- Q8083967 wikiPageWikiLink Q60147.
- Q8083967 wikiPageWikiLink Q6456072.
- Q8083967 wikiPageWikiLink Q6456086.
- Q8083967 wikiPageWikiLink Q6870315.
- Q8083967 wikiPageWikiLink Q7121197.
- Q8083967 wikiPageWikiLink Q742487.
- Q8083967 wikiPageWikiLink Q7441579.
- Q8083967 wikiPageWikiLink Q7669463.
- Q8083967 wikiPageWikiLink Q770260.
- Q8083967 wikiPageWikiLink Q83030.
- Q8083967 wikiPageWikiLink Q83871.
- Q8083967 wikiPageWikiLink Q852376.
- Q8083967 wikiPageWikiLink Q8872471.
- Q8083967 wikiPageWikiLink Q8965786.
- Q8083967 wikiPageWikiLink Q9672646.
- Q8083967 atcPrefix "none".
- Q8083967 casNumber "215874".
- Q8083967 drugName "α5IA".
- Q8083967 iupacName "3".
- Q8083967 pubchem "6918451".
- Q8083967 type ChemicalSubstance.
- Q8083967 type Drug.
- Q8083967 type ChemicalObject.
- Q8083967 type Thing.
- Q8083967 type Q8386.
- Q8083967 comment "α5IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABAA receptor.".
- Q8083967 label "Α5IA".
- Q8083967 depiction Alpha5IA.png.
- Q8083967 name "α5IA".